@entity3229 ( @entity3229 ) dysfunction has been implicated in the manifestation of many diseases and illnesses, ranging from @entity28 to @entity5 . Herein, we discuss the role of @entity19127 , one of the three @entity3229 isotypes, during wound healing. While @entity19127 expression is undetectable in unchallenged and healthy adult interfollicular @entity19 skin, it is robustly re-activated in stress situations, such as upon @entity4621 treatment, hair plucking and cutaneous wounding. The inflammatory reaction associated with a @entity272 activates the keratinocytes at the edges of the wound. This activation involves @entity19127 , whose expression and activity as transcription factor are up-regulated by pro-inflammatory signals. The re-activation of @entity19127 influences three important properties of the activated keratinocytes that are vital for rapid wound closure, namely, survival, migration and differentiation. The anti-apoptotic and, thus, survival role of @entity19127 is mediated by the up-regulation of expression of integrin-linked kinase and 3-phosphoinositide-dependent kinase-1. Both kinases are required for the full activation of the @entity1994 survival cascade. Therefore, the up-regulation of @entity19127 , early after injury, appears to be important to maintain a sufficient number of viable keratinocytes at the wound edge. At a later stage of wound repair, the stimulation of keratinocyte migration and differentiation by @entity19127 is also likely to be important for the formation of a new epidermis at the wounded area. Consistent with these observations, the entire wound healing process is delayed in @entity19127 +/- @entity19 and wound closure is retarded by 2-3 days. The multiple roles of @entity19127 in the complex keratinocyte response after injury and during skin repair certainly justify a further exploration of its potential as a target for wound healing drugs.

@entity3229 ( XXXX )-beta as a target for wound healing drugs: what is possible?

@entity3229 :: ('19013(Tax:10090)', 'Gene') :: ['Peroxisome proliferator-activated receptor', 'PPAR'] @entity19127 :: ('19015(Tax:10090)', 'Gene') :: ['PPARbeta'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity19 :: ('10090', 'Species') :: ['mice', 'mouse'] @entity4621 :: ('CHEBI:37532', 'Chemical') :: ['phorbol ester'] @entity1994 :: ('11651(Tax:10090)', 'Gene') :: ['Akt1'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin injury']
@entity3229 :: (19013(Tax:10090),Gene) :: ['PPAR']
